Abraxis Cited Again for cGMP Violations At Illinois Facility
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm tells “The Pink Sheet” DAILY it has taken “aggressive actions” in response to issues mentioned in a late 2006 FDA warning letter.